The acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is one of the most serious problems on the management of EGFR mutant lung cancer.
Introduction
Lung cancer is one of the most prevalent malignancies and the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) accounts for nearly 80% of lung cancer cases. Substantial efforts are being made to identify the optimal target for NSCLC therapy. The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib have been shown to inhibit epidermal growth factor receptor (EGFR) mediated downstream pathways including MAPK-ERK1/2 and PI3K-Akt, and to show favorable activity in NSCLC patients with mutant EGFR (1) . Recent phase III clinical trials demonstrated that patients with EGFR mutant NSCLC had superior outcomes with gefitinib treatment, compared with standard first line cytotoxic chemotherapy (2) (3) . However, the patients develop acquired resistance to EGFR-TKIs almost without exceptions within a couple of years (4) . In addition, 20-25% patients with EGFR activating mutations show intrinsic resistance to EGFR-TKIs.
Two genetically conferred mechanisms -T790M second mutation in EGFR (4) (5) , and the MET gene amplification (6) have been well reported to induce acquired resistance to EGFRTKIs in EGFR mutant lung cancer. Recently, we indentified a third mechanism, hepatocyte growth factor (HGF)-induced resistance. HGF induces EGFR-TKI resistance by activating MET which restores phosphorylation of downstream MAPK-ERK1/2 and PI3K-Akt pathways (7) (8) . This is not a genetically conferred mechanism, and may be involved in both intrinsic resistance and acquired resistance to EGFR-TKIs in EGFR mutant lung cancer (7) . While HGF is reported to be produced predominantly by stromal cells, it can act both autocrine and paracrine fashion when inducing resistance to EGFR-TKIs (7, 9) . More recent studies demonstrated that HGF is frequently co-expressed, along with the T790M second mutation in EGFR (10) and MET gene amplification (8) in tumors of patients with acquired resistance to EGFR-TKIs, indicating importance of HGF as therapeutic target for overcoming resistance to EGFR-TKIs.
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Author Manuscript Published OnlineFirst on January 10, 2011; DOI: 10.1158/1078-0432. CCR-10-1993 Several strategies are available to block HGF-MET mediated signaling, including ligand (HGF) blockade, MET tyrosine kinase inhibition, and inhibition of downstream molecules (PI3K/Akt, MAPK/ERK) (11) . PI3Ks are responsible for the generation of 3-phosphorylated inositides, including the important second messenger PtIns (3, 4, 5) P3, resulting in activation of signal transduction pathways in many physiologic process (12) . PI3Ks are divided into three classes based on their primary structures and in vitro substrate specificity (13) , with class I PI3Ks being the most well characterized. Class I PI3Ks can be further subdivided into class IA (p110α, p110β, and p110δ) and class IB (p110γ) according to their structure and interaction with p85 and p55 regulatory subunits. Class IA PI3Ks, each composed of a p85 regulatory subunit and a p110 catalytic subunit, are the most widely involved in cancer (14) . The major effector of PI3K in cancer is Akt, a serine-threonin kinase that is directly activated in response to PI3K (13) (14) . Recent studies indicate that the PI3K/Akt pathway plays crucial roles in resistance to various types of tyrosine kinase inhibitors, including EGFR TKIs (6, (15) (16) (17) . Accordingly, a large numbers of PI3K inhibitors are being developed (18) .
We sought to determine whether inhibition of PI3K signaling pathway could overcome EGFR-TKI resistance induced by HGF in EGFR mutant lung cancer. We found that transient exposure of class I PI3K inhibitor plus gefitinib was sufficient to overcome HGF-mediated resistance by inducing apoptosis of EGFR mutant lung cancer cells.
Research. Antibodies and Western blotting. For Western blotting analysis, 40 µg of total protein were resolved by SDS polyacrylamide gel (Bio-Rad) electrophoresis and the proteins were then transferred onto polyvinylidene difluoride membranes (Bio-Rad). After washing four times, membranes were incubated with Blocking One (Nacalai Tesque, Inc.) for 1h at room temperature and then incubated overnight at 4ºC with the following primary antibodies: anti-Met
Caspase-9 (Asp315),anti-Cleaved Caspase-3 (Asp175),anti-Cleaved PARP (Asp214) antibodies (1:1,000 dilution, Cell Signaling Technology), and anti-human EGFR (1 µg/mL), antihuman/mouse/rat extracellular signal-regulated kinase (ERK)-1/ERK2 (0.2 µg/mL), or antiphospho ERK1/ERK2 (T202/Y204) (0.1 µg/mL) antibodies (R&D Systems). After washing thrice, membranes were incubated for 1 h at room temperature with species specific horseradish
on Statistical Analysis. Two-tailed Student's t-test was performed when noted using GraphPad Software. Differences of P < 0.001 were considered statistically different (24) . We recently reported that HGF induce resistance in lung cancer cells (H1975) with EGFR T790M second mutation to irreversible EGFR-TKI which is expected to overcome T790M second mutation mediated resistance to gefitinib or erlotinib (25) . To explore the molecular mechanism by which PI-103 combined with gefitinib showed greater anti-proliferative effect, we examined the phosphorylation of MET, EGFR, ErbB3, and their downstream pathways (PI3K/Akt and ERK1/2) by Western blotting (Fig 3A) . PC-9 and HCC827 cells expressed EGFR, ErbB3, and MET proteins, and these molecules were phosphorylated at various levels. These receptors and downstream molecules, such as Akt and ERK1/2, were also phosphorylated. While HGF alone did not affect phosphorylation of EGFR or ErbB3, it stimulated phosphorylation of MET and thereby activated Akt and ERK1/2. Although gefitinib inhibited phosphorylation of Akt and ERK1/2 in the absence of HGF, it failed to inhibited Akt and ERK1/2 phosphorylation in the presence of HGF. Importantly, PI-103 did not affect the phosphorylation of ERK1/2 or upstream molecules such as MET, EGFR, and ErbB3, but did inhibit the phosphotylation of Akt, regardless of presence of HGF. In addition, PI-103 combined with gefitinib inhibited phosphorylation of both Akt and ERK1/2 in the absence of HGF. The combination of PI-103 and gefitinib inhibited Akt phosphorylation, even in the presence of HGF, but failed to inhibit ERK1/2 phosphorylation. These results confirm our previous observations (7) and further suggest that PI-103 overcomes this resistance by inhibiting phosphorylation of downstream PI3K/Akt. The importance of PI3K/Akt as a target of PI-103 was further supported the evidence obtained in experiments with siRNA for Akt. Treatment with siAkt1 alone knock downed the Akt expression in PC-9 cells (Fig 3B) and resulted in inhibition of cell proliferation by 20% (Fig 3C) . Notably, the treatment with siAkt1 reversed HGF-induced gefitinib resistance in combination with gefitinib ( Fig 3C) .
Results
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PI-103 combined with gefitinib overcomes HGF-induced gefitinib-resistance in vivo.
We recently established an in vivo model by inoculating PC-9 cells pre-mixed with HGF-high producing MRC-5 cells and showed that gefitinib resistance which was abrogated by HGF-MET inhibition (9) . Using this model, we next evaluated whether PI-103 overcomes HGF-induced resistance to gefitinib in vivo. Consistent with previous observations, we found that treatment with gefitinib alone prevented the enlargement of tumors produced by the mixture of PC-9 cells (Fig 4,   A and B) . Similar results were reproduced using GDC-0941 which is now used in clinical trials in patients with solid tumors (Supplementary Fig. 4 ). These combined treatments did not cause obvious side effects, such as weight loss of the mice.
We further examined apoptotic cells in the tumors treated with gefitinib and/or PI-103. While there were few apoptotic cells in control- (Fig 4C) or PI-103-treated tumors (Fig 4D) , discernible numbers of apoptotic cells were detected in gefitinib-treated tumors (Fig 4E) . However, more apoptotic cells were found in tumors treated with both PI-103 and gefitinib ( Fig 4F) . (Fig 4 A, B) .
Immunoblots using these tumors revealed that treatment with PI-103 with or without gefitinib, did not affect the phosphorylation of ERK1/2. On the other hand, PI-103 alone or in combination with gefitinib inhibited Akt phosphorylation in the tumor. Most notably, PI-103 combined with gefitinib induced cleaved caspase 3, the effector caspase that mediate death signaling (Fig 4 G) .
These results strongly suggested the importance of PI3K/Akt as a target of this combined therapy.
Short exposure of PI-103 combined with gefitinib further inhibits Akt mediating signal and proliferation of EGFR mutant lung cancer cells
Our finding, that PI-103 monotherapy did not inhibit tumor growth whereas PI-103 overcame synergistically HGF (MRC-5)-induced gefitinib resistance when combined with gefitinib, was unexpected. Since PI-103 has been reported to have very rapid tissue distribution and tissue clearance in vivo (half life of PI-103 in the major organs is 0.7-1.3h) (12), we hypothesized that rapid tissue clearance of PI-103 might be responsible for its insufficient therapeutic effect in vivo.
To mimic pharmacodynamics of PI-103 in vivo, we exposed PC-9 and HCC827 cells to PI-103
on 1993 transiently for 1h, then washed the cells and incubated the resultant cultures in fresh medium for 48h (Fig 5A) . Transient exposure to PI-103 resulted in only ~15% inhibition of the proliferation of PC-9 or HCC827 cells, whereas transient exposure to gefitinib resulted in higher inhibition of proliferation (> 30%). Importantly, transient exposure to both PI-103 and gefitinib inhibited the proliferation of these two cell lines, reaching IC50 (Fig 5B) . Analysis using CalcuSyn software (23) indicates that the effect was synergistic. These phenomena were also observed when EGFR mutant cancer cells were co-cultured with MRC-5 cells (Fig 5C) to induce gefitinib resistance, representing the therapeutic efficacy seen in vivo model. By contrast, transient exposure to PI-103 and/or gefitinib did not inhibit proliferation of MRC-5 cells (Fig 5D) .
We further evaluated the kinetics of PI3K/Akt phosphorylation after transient exposure of PC-9 cells to PI-103 and gefitinib ( Fig 6A) . As shown above (Fig 3) , 1h treatment with either PI-103 or gefitinib completely inhibited Akt phosphorylation, in the absence of HGF. We found out that, in the absence of HGF, gefitinib, alone or combined with PI-103, inhibited Akt phosphorylation for up to 1h; subsequently, however, Akt phosphorylation in PC-9 cells treated with PI-103 alone started to recover. In the presence of HGF, gefitinib did not inhibit Akt phosphorylation, whereas Akt phosphorylation in PC-9 cells treated with PI-103 alone recovered by 1h after washing.
However, cells treated with PI-103 plus gefitinib showed inhibition of Akt phosphorylation 1h after washing (Fig 6A) . More importantly, transient exposure to PI-103 plus gefitinib, but not either alone, resulted in induction of cleaved caspase 9 and 3, the initiator and effector caspases that mediate death signaling, and cleaved PARP (Fig 6A) . Further experiments are warranted to clarify the mechanisms in future.
PI-103 is a class I PI3K inhibitor that reported favorable antitumor activity without any obvious side effects in preclinical animal models (12, 32) . Pharmacokinetically, PI-103 is metabolized to form glucuronide and is cleared rapidly from plasma, with metabolysis of >70% PI-103 after 30min of incubation with human and mouse microsomes (12) . This is consistent with our results showing that Akt phosphorylation in PC-9 cells treated with PI-103 alone was recovered by 1h (Fig 6) . PI-103 is not in clinical trials and work is now in progress to optimize its pharmacokinetics properties by structural modification (13) . While continuous exposure for 72h of PI-103 inhibited the proliferation of PC-9 and HCC827 cells, transient exposure for 1h of PI-103 failed to do so in vitro condition. In vivo treatment with PI-103 (5mg/kg i.p., once a day) also failed to inhibit the growth of PC-9 cells mixed with HGF-high producing fibroblasts (MRC-5).
Collectively, the insufficient effect of PI-103 monotherapy may be, at least in part, due to short half life and rapid metabolism of this drug in vivo. GDC-0941 (5mg/kg p.o., once a day) also failed to inhibit the growth of PC-9 cells mixed with MRC-5 cells. Though GDC-0941 is a derivative of PI -103 with improved pharmacokinetic and pharmacodynamic properties, intratumoral concentration of GDC-0941 might not be enough to inhibit tumor growth in our in vivo experimental conditions. However, GDC-0941, like PI-103, successfully reversed the resistance when combined with gefitinib ( Supplementary Fig 4) . Since we did not use maximum -1993 combined use of PI3K inhibitor may also protect against the emergence of reversibly tolerant subpopulations and may potently eradicate EGFR mutant lung cancer. Further investigations in PI3K-Akt signaling pathway are warranted for developing more successful compounds with better activity and safety for EGFR mutant lung cancer patients.
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